-
1
-
-
37849032623
-
Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells
-
Airas L., Saraste M., Rinta S., Elovaara I., Huang Y.H., Wiendl H. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin. Exp. Immunol. 2008, 151(2):235-243.
-
(2008)
Clin. Exp. Immunol.
, vol.151
, Issue.2
, pp. 235-243
-
-
Airas, L.1
Saraste, M.2
Rinta, S.3
Elovaara, I.4
Huang, Y.H.5
Wiendl, H.6
-
2
-
-
2942537826
-
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta
-
Bielekova B., Richert N., Howard T., Blevins G., Markovic-Plese S., McCartin J., Frank J.A., Wurfel J., Ohayon J., Waldmann T.A., McFarland H.F., Martin R. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(23):8705-8708.
-
(2004)
Proc. Natl. Acad. Sci. U. S. A.
, vol.101
, Issue.23
, pp. 8705-8708
-
-
Bielekova, B.1
Richert, N.2
Howard, T.3
Blevins, G.4
Markovic-Plese, S.5
McCartin, J.6
Frank, J.A.7
Wurfel, J.8
Ohayon, J.9
Waldmann, T.A.10
McFarland, H.F.11
Martin, R.12
-
3
-
-
33645812129
-
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis
-
Bielekova B., Catalfamo M., Reichert-Scrivner S., Packer A., Cerna M., Waldmann T.A., McFarland H., Henkart P.A., Martin R. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(15):5941-5946.
-
(2006)
Proc. Natl. Acad. Sci. U. S. A.
, vol.103
, Issue.15
, pp. 5941-5946
-
-
Bielekova, B.1
Catalfamo, M.2
Reichert-Scrivner, S.3
Packer, A.4
Cerna, M.5
Waldmann, T.A.6
McFarland, H.7
Henkart, P.A.8
Martin, R.9
-
4
-
-
65249138318
-
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis
-
Bielekova B., Howard T., Packer A.N., Richert N., Blevins G., Ohayon J., Waldmann T.A., McFarland H.F., Martin R. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch. Neurol. 2009, 66(4):483-489.
-
(2009)
Arch. Neurol.
, vol.66
, Issue.4
, pp. 483-489
-
-
Bielekova, B.1
Howard, T.2
Packer, A.N.3
Richert, N.4
Blevins, G.5
Ohayon, J.6
Waldmann, T.A.7
McFarland, H.F.8
Martin, R.9
-
5
-
-
82955225356
-
Intrathecal effects of daclizumab treatment of multiple sclerosis
-
Bielekova B., Richert N., Herman M.L., Ohayon J., Waldmann T.A., McFarland H., Martin R., Blevins G. Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology 2011, 77(21):1877-1886.
-
(2011)
Neurology
, vol.77
, Issue.21
, pp. 1877-1886
-
-
Bielekova, B.1
Richert, N.2
Herman, M.L.3
Ohayon, J.4
Waldmann, T.A.5
McFarland, H.6
Martin, R.7
Blevins, G.8
-
6
-
-
84861022041
-
Risk of natalizumab-associated progressive multifocal leukoencephalopathy
-
Bloomgren G., Richman S., Hotermans C., Subramanyam M., Goelz S., Natarajan A., Lee S., Plavina T., Scanlon J.V., Sandrock A., Bozic C. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 2012, 366(20):1870-1880.
-
(2012)
N. Engl. J. Med.
, vol.366
, Issue.20
, pp. 1870-1880
-
-
Bloomgren, G.1
Richman, S.2
Hotermans, C.3
Subramanyam, M.4
Goelz, S.5
Natarajan, A.6
Lee, S.7
Plavina, T.8
Scanlon, J.V.9
Sandrock, A.10
Bozic, C.11
-
7
-
-
26044436515
-
Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood
-
Bratke K., Kuepper M., Bade B., Virchow J.C., Luttmann W. Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood. Eur. J. Immunol. 2005, 35(9):2608-2616.
-
(2005)
Eur. J. Immunol.
, vol.35
, Issue.9
, pp. 2608-2616
-
-
Bratke, K.1
Kuepper, M.2
Bade, B.3
Virchow, J.C.4
Luttmann, W.5
-
8
-
-
70149089482
-
Asymptomatic reactivation of JC virus in patients treated with natalizumab
-
Chen Y., Bord E., Tompkins T., Miller J., Tan C.S., Kinkel R.P., Stein M.C., Viscidi R.P., Ngo L.H., Koralnik I.J. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N. Engl. J. Med. 2009, 361(11):1067-1074.
-
(2009)
N. Engl. J. Med.
, vol.361
, Issue.11
, pp. 1067-1074
-
-
Chen, Y.1
Bord, E.2
Tompkins, T.3
Miller, J.4
Tan, C.S.5
Kinkel, R.P.6
Stein, M.C.7
Viscidi, R.P.8
Ngo, L.H.9
Koralnik, I.J.10
-
9
-
-
76149140914
-
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
-
Cohen J.A., Barkhof F., Comi G., Hartung H.P., Khatri B.O., Montalban X., Pelletier J., Capra R., Gallo P., Izquierdo G., Tiel-Wilck K., de Vera A., Jin J., Stites T., Wu S., Aradhye S., Kappos L. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362(5):402-415.
-
(2010)
N. Engl. J. Med.
, vol.362
, Issue.5
, pp. 402-415
-
-
Cohen, J.A.1
Barkhof, F.2
Comi, G.3
Hartung, H.P.4
Khatri, B.O.5
Montalban, X.6
Pelletier, J.7
Capra, R.8
Gallo, P.9
Izquierdo, G.10
Tiel-Wilck, K.11
de Vera, A.12
Jin, J.13
Stites, T.14
Wu, S.15
Aradhye, S.16
Kappos, L.17
-
10
-
-
84869492471
-
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
-
Cohen J.A., Coles A.J., Arnold D.L., Confavreux C., Fox E.J., Hartung H.P., Havrdova E., Selmaj K.W., Weiner H.L., Fisher E., Brinar V.V., Giovannoni G., Stojanovic M., Ertik B.I., Lake S.L., Margolin D.H., Panzara M.A., Compston D.A. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012, 380(9856):1819-1828.
-
(2012)
Lancet
, vol.380
, Issue.9856
, pp. 1819-1828
-
-
Cohen, J.A.1
Coles, A.J.2
Arnold, D.L.3
Confavreux, C.4
Fox, E.J.5
Hartung, H.P.6
Havrdova, E.7
Selmaj, K.W.8
Weiner, H.L.9
Fisher, E.10
Brinar, V.V.11
Giovannoni, G.12
Stojanovic, M.13
Ertik, B.I.14
Lake, S.L.15
Margolin, D.H.16
Panzara, M.A.17
Compston, D.A.18
-
11
-
-
84869507357
-
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
-
Coles A.J., Twyman C.L., Arnold D.L., Cohen J.A., Confavreux C., Fox E.J., Hartung H.P., Havrdova E., Selmaj K.W., Weiner H.L., Miller T., Fisher E., Sandbrink R., Lake S.L., Margolin D.H., Oyuela P., Panzara M.A., Compston D.A. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012, 380(9856):1829-1839.
-
(2012)
Lancet
, vol.380
, Issue.9856
, pp. 1829-1839
-
-
Coles, A.J.1
Twyman, C.L.2
Arnold, D.L.3
Cohen, J.A.4
Confavreux, C.5
Fox, E.J.6
Hartung, H.P.7
Havrdova, E.8
Selmaj, K.W.9
Weiner, H.L.10
Miller, T.11
Fisher, E.12
Sandbrink, R.13
Lake, S.L.14
Margolin, D.H.15
Oyuela, P.16
Panzara, M.A.17
Compston, D.A.18
-
12
-
-
0037029424
-
Multiple sclerosis
-
Compston A., Coles A. Multiple sclerosis. Lancet 2002, 359(9313):1221-1231.
-
(2002)
Lancet
, vol.359
, Issue.9313
, pp. 1221-1231
-
-
Compston, A.1
Coles, A.2
-
14
-
-
0035874522
-
Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset
-
Cooper M.A., Fehniger T.A., Turner S.C., Chen K.S., Ghaheri B.A., Ghayur T., Carson W.E., Caligiuri M.A. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001, 97(10):3146-3151.
-
(2001)
Blood
, vol.97
, Issue.10
, pp. 3146-3151
-
-
Cooper, M.A.1
Fehniger, T.A.2
Turner, S.C.3
Chen, K.S.4
Ghaheri, B.A.5
Ghayur, T.6
Carson, W.E.7
Caligiuri, M.A.8
-
15
-
-
0038082247
-
The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors
-
Della Chiesa M., Vitale M., Carlomagno S., Ferlazzo G., Moretta L., Moretta A. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur. J. Immunol. 2003, 33(6):1657-1666.
-
(2003)
Eur. J. Immunol.
, vol.33
, Issue.6
, pp. 1657-1666
-
-
Della Chiesa, M.1
Vitale, M.2
Carlomagno, S.3
Ferlazzo, G.4
Moretta, L.5
Moretta, A.6
-
16
-
-
0024614839
-
Immunotherapy of experimental autoimmune encephalomyelitis (EAE): differential effect of anti-IL-2 receptor antibody therapy on actively induced and T-line mediated EAE of the Lewis rat
-
Engelhardt B., Diamantstein T., Wekerle H. Immunotherapy of experimental autoimmune encephalomyelitis (EAE): differential effect of anti-IL-2 receptor antibody therapy on actively induced and T-line mediated EAE of the Lewis rat. J. Autoimmun. 1989, 2(1):61-73.
-
(1989)
J. Autoimmun.
, vol.2
, Issue.1
, pp. 61-73
-
-
Engelhardt, B.1
Diamantstein, T.2
Wekerle, H.3
-
17
-
-
84886414834
-
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
-
(CD008933)
-
Filippini G., Del Giovane C., Vacchi L., D'Amico R., Di Pietrantonj C., Beecher D., Salanti G. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst. Rev. 2013, 6. (CD008933).
-
(2013)
Cochrane Database Syst. Rev.
, vol.6
-
-
Filippini, G.1
Del Giovane, C.2
Vacchi, L.3
D'Amico, R.4
Di Pietrantonj, C.5
Beecher, D.6
Salanti, G.7
-
18
-
-
84866355653
-
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis
-
Fox R.J., Miller D.H., Phillips J.T., Hutchinson M., Havrdova E., Kita M., Yang M., Raghupathi K., Novas M., Sweetser M.T., Viglietta V., Dawson K.T. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 2012, 367(12):1087-1097.
-
(2012)
N. Engl. J. Med.
, vol.367
, Issue.12
, pp. 1087-1097
-
-
Fox, R.J.1
Miller, D.H.2
Phillips, J.T.3
Hutchinson, M.4
Havrdova, E.5
Kita, M.6
Yang, M.7
Raghupathi, K.8
Novas, M.9
Sweetser, M.T.10
Viglietta, V.11
Dawson, K.T.12
-
19
-
-
20144371569
-
A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells
-
Freud A.G., Becknell B., Roychowdhury S., Mao H.C., Ferketich A.K., Nuovo G.J., Hughes T.L., Marburger T.B., Sung J., Baiocchi R.A., Guimond M., Caligiuri M.A. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity 2005, 22(3):295-304.
-
(2005)
Immunity
, vol.22
, Issue.3
, pp. 295-304
-
-
Freud, A.G.1
Becknell, B.2
Roychowdhury, S.3
Mao, H.C.4
Ferketich, A.K.5
Nuovo, G.J.6
Hughes, T.L.7
Marburger, T.B.8
Sung, J.9
Baiocchi, R.A.10
Guimond, M.11
Caligiuri, M.A.12
-
20
-
-
78649826782
-
Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved
-
Gold R. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. CNS Drugs 2011, 25(1):37-52.
-
(2011)
CNS Drugs
, vol.25
, Issue.1
, pp. 37-52
-
-
Gold, R.1
-
21
-
-
84866423965
-
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis
-
Gold R., Kappos L., Arnold D.L., Bar-Or A., Giovannoni G., Selmaj K., Tornatore C., Sweetser M.T., Yang M., Sheikh S.I., Dawson K.T. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 2012, 367(12):1098-1107.
-
(2012)
N. Engl. J. Med.
, vol.367
, Issue.12
, pp. 1098-1107
-
-
Gold, R.1
Kappos, L.2
Arnold, D.L.3
Bar-Or, A.4
Giovannoni, G.5
Selmaj, K.6
Tornatore, C.7
Sweetser, M.T.8
Yang, M.9
Sheikh, S.I.10
Dawson, K.T.11
-
22
-
-
84879239117
-
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
-
Gold R., Giovannoni G., Selmaj K., Havrdova E., Montalban X., Radue E.W., Stefoski D., Robinson R., Riester K., Rana J., Elkins J., O'Neill G. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 2013, 381(9884):2167-2175.
-
(2013)
Lancet
, vol.381
, Issue.9884
, pp. 2167-2175
-
-
Gold, R.1
Giovannoni, G.2
Selmaj, K.3
Havrdova, E.4
Montalban, X.5
Radue, E.W.6
Stefoski, D.7
Robinson, R.8
Riester, K.9
Rana, J.10
Elkins, J.11
O'Neill, G.12
-
23
-
-
34548299105
-
Risk alleles for multiple sclerosis identified by a genomewide study
-
Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., De Jager P.L., de Bakker P.I., Gabriel S.B., Mirel D.B., Ivinson A.J., Pericak-Vance M.A., Gregory S.G., Rioux J.D., McCauley J.L., Haines J.L., Barcellos L.F., Cree B., Oksenberg J.R., Hauser S.L. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 2007, 357(9):851-862.
-
(2007)
N. Engl. J. Med.
, vol.357
, Issue.9
, pp. 851-862
-
-
Hafler, D.A.1
Compston, A.2
Sawcer, S.3
Lander, E.S.4
Daly, M.J.5
De Jager, P.L.6
de Bakker, P.I.7
Gabriel, S.B.8
Mirel, D.B.9
Ivinson, A.J.10
Pericak-Vance, M.A.11
Gregory, S.G.12
Rioux, J.D.13
McCauley, J.L.14
Haines, J.L.15
Barcellos, L.F.16
Cree, B.17
Oksenberg, J.R.18
Hauser, S.L.19
-
24
-
-
84871152858
-
IL-7 abrogates suppressive activity of human CD4+CD25+FOXP3+ regulatory T cells and allows expansion of alloreactive and autoreactive T cells
-
Heninger A.K., Theil A., Wilhelm C., Petzold C., Huebel N., Kretschmer K., Bonifacio E., Monti P. IL-7 abrogates suppressive activity of human CD4+CD25+FOXP3+ regulatory T cells and allows expansion of alloreactive and autoreactive T cells. J. Immunol. 2012, 189(12):5649-5658.
-
(2012)
J. Immunol.
, vol.189
, Issue.12
, pp. 5649-5658
-
-
Heninger, A.K.1
Theil, A.2
Wilhelm, C.3
Petzold, C.4
Huebel, N.5
Kretschmer, K.6
Bonifacio, E.7
Monti, P.8
-
25
-
-
79960547202
-
Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis
-
Jiang W., Chai N.R., Maric D., Bielekova B. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J. Immunol. 2011, 187(2):781-790.
-
(2011)
J. Immunol.
, vol.187
, Issue.2
, pp. 781-790
-
-
Jiang, W.1
Chai, N.R.2
Maric, D.3
Bielekova, B.4
-
26
-
-
0031770389
-
Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac
-
Lehky T.J., Levin M.C., Kubota R., Bamford R.N., Flerlage A.N., Soldan S.S., Leist T.P., Xavier A., White J.D., Brown M., Fleisher T.A., Top L.E., Light S., McFarland H.F., Waldmann T.A., Jacobson S. Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. Ann. Neurol. 1998, 44(6):942-947.
-
(1998)
Ann. Neurol.
, vol.44
, Issue.6
, pp. 942-947
-
-
Lehky, T.J.1
Levin, M.C.2
Kubota, R.3
Bamford, R.N.4
Flerlage, A.N.5
Soldan, S.S.6
Leist, T.P.7
Xavier, A.8
White, J.D.9
Brown, M.10
Fleisher, T.A.11
Top, L.E.12
Light, S.13
McFarland, H.F.14
Waldmann, T.A.15
Jacobson, S.16
-
27
-
-
0029414791
-
Role of the common cytokine receptor gamma chain in cytokine signaling and lymphoid development
-
Leonard W.J., Shores E.W., Love P.E. Role of the common cytokine receptor gamma chain in cytokine signaling and lymphoid development. Immunol. Rev. 1995, 148:97-114.
-
(1995)
Immunol. Rev.
, vol.148
, pp. 97-114
-
-
Leonard, W.J.1
Shores, E.W.2
Love, P.E.3
-
28
-
-
17844364666
-
Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis
-
Li Z., Lim W.K., Mahesh S.P., Liu B., Nussenblatt R.B. Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J. Immunol. 2005, 174(9):5187-5191.
-
(2005)
J. Immunol.
, vol.174
, Issue.9
, pp. 5187-5191
-
-
Li, Z.1
Lim, W.K.2
Mahesh, S.P.3
Liu, B.4
Nussenblatt, R.B.5
-
29
-
-
84872790689
-
Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy
-
Liao W., Lin J.X., Leonard W.J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013, 38(1):13-25.
-
(2013)
Immunity
, vol.38
, Issue.1
, pp. 13-25
-
-
Liao, W.1
Lin, J.X.2
Leonard, W.J.3
-
30
-
-
34548367511
-
Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes
-
Lowe C.E., Cooper J.D., Brusko T., Walker N.M., Smyth D.J., Bailey R., Bourget K., Plagnol V., Field S., Atkinson M., Clayton D.G., Wicker L.S., Todd J.A. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat. Genet. 2007, 39(9):1074-1082.
-
(2007)
Nat. Genet.
, vol.39
, Issue.9
, pp. 1074-1082
-
-
Lowe, C.E.1
Cooper, J.D.2
Brusko, T.3
Walker, N.M.4
Smyth, D.J.5
Bailey, R.6
Bourget, K.7
Plagnol, V.8
Field, S.9
Atkinson, M.10
Clayton, D.G.11
Wicker, L.S.12
Todd, J.A.13
-
31
-
-
83155173565
-
Inflammatory cortical demyelination in early multiple sclerosis
-
Lucchinetti C.F., Popescu B.F., Bunyan R.F., Moll N.M., Roemer S.F., Lassmann H., Bruck W., Parisi J.E., Scheithauer B.W., Giannini C., Weigand S.D., Mandrekar J., Ransohoff R.M. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 2011, 365(23):2188-2197.
-
(2011)
N. Engl. J. Med.
, vol.365
, Issue.23
, pp. 2188-2197
-
-
Lucchinetti, C.F.1
Popescu, B.F.2
Bunyan, R.F.3
Moll, N.M.4
Roemer, S.F.5
Lassmann, H.6
Bruck, W.7
Parisi, J.E.8
Scheithauer, B.W.9
Giannini, C.10
Weigand, S.D.11
Mandrekar, J.12
Ransohoff, R.M.13
-
32
-
-
58749107371
-
Human NK cells kill resting but not activated microglia via NKG2D- and NKp46-mediated recognition
-
Lunemann A., Lunemann J.D., Roberts S., Messmer B., Barreira da Silva R., Raine C.S., Munz C. Human NK cells kill resting but not activated microglia via NKG2D- and NKp46-mediated recognition. J. Immunol. 2008, 181(9):6170-6177.
-
(2008)
J. Immunol.
, vol.181
, Issue.9
, pp. 6170-6177
-
-
Lunemann, A.1
Lunemann, J.D.2
Roberts, S.3
Messmer, B.4
Barreira da Silva, R.5
Raine, C.S.6
Munz, C.7
-
33
-
-
58949100205
-
IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production
-
Maier L.M., Lowe C.E., Cooper J., Downes K., Anderson D.E., Severson C., Clark P.M., Healy B., Walker N., Aubin C., Oksenberg J.R., Hauser S.L., Compston A., Sawcer S., De Jager P.L., Wicker L.S., Todd J.A., Hafler D.A. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet. 2009, 5(1):e1000322.
-
(2009)
PLoS Genet.
, vol.5
, Issue.1
, pp. e1000322
-
-
Maier, L.M.1
Lowe, C.E.2
Cooper, J.3
Downes, K.4
Anderson, D.E.5
Severson, C.6
Clark, P.M.7
Healy, B.8
Walker, N.9
Aubin, C.10
Oksenberg, J.R.11
Hauser, S.L.12
Compston, A.13
Sawcer, S.14
De Jager, P.L.15
Wicker, L.S.16
Todd, J.A.17
Hafler, D.A.18
-
34
-
-
41949097030
-
The biology of interleukin-2
-
Malek T.R. The biology of interleukin-2. Annu. Rev. Immunol. 2008, 26:453-479.
-
(2008)
Annu. Rev. Immunol.
, vol.26
, pp. 453-479
-
-
Malek, T.R.1
-
35
-
-
77951828930
-
Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
-
Marriott J.J., Miyasaki J.M., Gronseth G., O'Connor P.W. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010, 74(18):1463-1470.
-
(2010)
Neurology
, vol.74
, Issue.18
, pp. 1463-1470
-
-
Marriott, J.J.1
Miyasaki, J.M.2
Gronseth, G.3
O'Connor, P.W.4
-
36
-
-
84863410319
-
Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis
-
Martin R. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clin. Immunol. 2012, 142(1):9-14.
-
(2012)
Clin. Immunol.
, vol.142
, Issue.1
, pp. 9-14
-
-
Martin, R.1
-
37
-
-
77955506880
-
An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells
-
Martin J.F., Perry J.S., Jakhete N.R., Wang X., Bielekova B. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J. Immunol. 2010, 185(2):1311-1320.
-
(2010)
J. Immunol.
, vol.185
, Issue.2
, pp. 1311-1320
-
-
Martin, J.F.1
Perry, J.S.2
Jakhete, N.R.3
Wang, X.4
Bielekova, B.5
-
38
-
-
34548133584
-
Multiple sclerosis: a complicated picture of autoimmunity
-
McFarland H.F., Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 2007, 8(9):913-919.
-
(2007)
Nat. Immunol.
, vol.8
, Issue.9
, pp. 913-919
-
-
McFarland, H.F.1
Martin, R.2
-
39
-
-
13044311376
-
Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial
-
Nussenblatt R.B., Fortin E., Schiffman R., Rizzo L., Smith J., Van Veldhuisen P., Sran P., Yaffe A., Goldman C.K., Waldmann T.A., Whitcup S.M. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(13):7462-7466.
-
(1999)
Proc. Natl. Acad. Sci. U. S. A.
, vol.96
, Issue.13
, pp. 7462-7466
-
-
Nussenblatt, R.B.1
Fortin, E.2
Schiffman, R.3
Rizzo, L.4
Smith, J.5
Van Veldhuisen, P.6
Sran, P.7
Yaffe, A.8
Goldman, C.K.9
Waldmann, T.A.10
Whitcup, S.M.11
-
40
-
-
10744222484
-
Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration
-
Nussenblatt R.B., Thompson D.J., Li Z., Chan C.C., Peterson J.S., Robinson R.R., Shames R.S., Nagarajan S., Tang M.T., Mailman M., Velez G., Roy C., Levy-Clarke G.A., Suhler E.B., Djalilian A., Sen H.N., Al-Khatib S., Ursea R., Srivastava S., Bamji A., Mellow S., Sran P., Waldmann T.A., Buggage R.R. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J. Autoimmun. 2003, 21(3):283-293.
-
(2003)
J. Autoimmun.
, vol.21
, Issue.3
, pp. 283-293
-
-
Nussenblatt, R.B.1
Thompson, D.J.2
Li, Z.3
Chan, C.C.4
Peterson, J.S.5
Robinson, R.R.6
Shames, R.S.7
Nagarajan, S.8
Tang, M.T.9
Mailman, M.10
Velez, G.11
Roy, C.12
Levy-Clarke, G.A.13
Suhler, E.B.14
Djalilian, A.15
Sen, H.N.16
Al-Khatib, S.17
Ursea, R.18
Srivastava, S.19
Bamji, A.20
Mellow, S.21
Sran, P.22
Waldmann, T.A.23
Buggage, R.R.24
more..
-
41
-
-
80053533877
-
Randomized trial of oral teriflunomide for relapsing multiple sclerosis
-
O'Connor P., Wolinsky J.S., Confavreux C., Comi G., Kappos L., Olsson T.P., Benzerdjeb H., Truffinet P., Wang L., Miller A., Freedman M.S. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 2011, 365(14):1293-1303.
-
(2011)
N. Engl. J. Med.
, vol.365
, Issue.14
, pp. 1293-1303
-
-
O'Connor, P.1
Wolinsky, J.S.2
Confavreux, C.3
Comi, G.4
Kappos, L.5
Olsson, T.P.6
Benzerdjeb, H.7
Truffinet, P.8
Wang, L.9
Miller, A.10
Freedman, M.S.11
-
42
-
-
65249155884
-
Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis
-
Oh U., Blevins G., Griffith C., Richert N., Maric D., Lee C.R., McFarland H., Jacobson S. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch. Neurol. 2009, 66(4):471-479.
-
(2009)
Arch. Neurol.
, vol.66
, Issue.4
, pp. 471-479
-
-
Oh, U.1
Blevins, G.2
Griffith, C.3
Richert, N.4
Maric, D.5
Lee, C.R.6
McFarland, H.7
Jacobson, S.8
-
43
-
-
84864558396
-
Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis
-
145ra106
-
Perry J.S., Han S., Xu Q., Herman M.L., Kennedy L.B., Csako G., Bielekova B. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci. Transl. Med. 2012, 4(145):145ra106.
-
(2012)
Sci. Transl. Med.
, vol.4
, Issue.145
-
-
Perry, J.S.1
Han, S.2
Xu, Q.3
Herman, M.L.4
Kennedy, L.B.5
Csako, G.6
Bielekova, B.7
-
44
-
-
84878303057
-
Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis
-
Pfender N., Saccardi R., Martin R. Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis. Curr. Treat. Options Neurol. 2013, 15(3):270-280.
-
(2013)
Curr. Treat. Options Neurol.
, vol.15
, Issue.3
, pp. 270-280
-
-
Pfender, N.1
Saccardi, R.2
Martin, R.3
-
45
-
-
33644584352
-
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
-
Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovannoni G., Wajgt A., Toal M., Lynn F., Panzara M.A., Sandrock A.W. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 354(9):899-910.
-
(2006)
N. Engl. J. Med.
, vol.354
, Issue.9
, pp. 899-910
-
-
Polman, C.H.1
O'Connor, P.W.2
Havrdova, E.3
Hutchinson, M.4
Kappos, L.5
Miller, D.H.6
Phillips, J.T.7
Lublin, F.D.8
Giovannoni, G.9
Wajgt, A.10
Toal, M.11
Lynn, F.12
Panzara, M.A.13
Sandrock, A.W.14
-
46
-
-
84896722910
-
Basiliximab: efficacy and safety evaluation in kidney transplantation
-
Ponticelli C. Basiliximab: efficacy and safety evaluation in kidney transplantation. Expert Opin. Drug Saf. 2014, 13(3):373-381.
-
(2014)
Expert Opin. Drug Saf.
, vol.13
, Issue.3
, pp. 373-381
-
-
Ponticelli, C.1
-
47
-
-
77953464476
-
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis
-
Rojas M.A., Carlson N.G., Miller T.L., Rose J.W. Long-term daclizumab therapy in relapsing-remitting multiple sclerosis. Ther. Adv. Neurol. Disord. 2009, 2(5):291-297.
-
(2009)
Ther. Adv. Neurol. Disord.
, vol.2
, Issue.5
, pp. 291-297
-
-
Rojas, M.A.1
Carlson, N.G.2
Miller, T.L.3
Rose, J.W.4
-
48
-
-
9644265478
-
Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody
-
Rose J.W., Watt H.E., White A.T., Carlson N.G. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann. Neurol. 2004, 56(6):864-867.
-
(2004)
Ann. Neurol.
, vol.56
, Issue.6
, pp. 864-867
-
-
Rose, J.W.1
Watt, H.E.2
White, A.T.3
Carlson, N.G.4
-
49
-
-
34548142973
-
Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results
-
Rose J.W., Burns J.B., Bjorklund J., Klein J., Watt H.E., Carlson N.G. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007, 69(8):785-789.
-
(2007)
Neurology
, vol.69
, Issue.8
, pp. 785-789
-
-
Rose, J.W.1
Burns, J.B.2
Bjorklund, J.3
Klein, J.4
Watt, H.E.5
Carlson, N.G.6
-
50
-
-
0027369395
-
Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene
-
Sadlack B., Merz H., Schorle H., Schimpl A., Feller A.C., Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993, 75(2):253-261.
-
(1993)
Cell
, vol.75
, Issue.2
, pp. 253-261
-
-
Sadlack, B.1
Merz, H.2
Schorle, H.3
Schimpl, A.4
Feller, A.C.5
Horak, I.6
-
51
-
-
0028783963
-
Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells
-
Sadlack B., Lohler J., Schorle H., Klebb G., Haber H., Sickel E., Noelle R.J., Horak I. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur. J. Immunol. 1995, 25(11):3053-3059.
-
(1995)
Eur. J. Immunol.
, vol.25
, Issue.11
, pp. 3053-3059
-
-
Sadlack, B.1
Lohler, J.2
Schorle, H.3
Klebb, G.4
Haber, H.5
Sickel, E.6
Noelle, R.J.7
Horak, I.8
-
52
-
-
84875218285
-
Innate lymphoid cells: from border protection to the initiation of inflammatory diseases
-
Sanos S.L., Diefenbach A. Innate lymphoid cells: from border protection to the initiation of inflammatory diseases. Immunol. Cell Biol. 2013, 91(3):215-224.
-
(2013)
Immunol. Cell Biol.
, vol.91
, Issue.3
, pp. 215-224
-
-
Sanos, S.L.1
Diefenbach, A.2
-
53
-
-
79955695969
-
Window of opportunity for daclizumab
-
Schluns K.S. Window of opportunity for daclizumab. Nat. Med. 2011, 17(5):545-547.
-
(2011)
Nat. Med.
, vol.17
, Issue.5
, pp. 545-547
-
-
Schluns, K.S.1
-
54
-
-
82555171610
-
Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis
-
Sheridan J.P., Zhang Y., Riester K., Tang M.T., Efros L., Shi J., Harris J., Vexler V., Elkins J.S. Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis. Mult. Scler. 2011, 17(12):1441-1448.
-
(2011)
Mult. Scler.
, vol.17
, Issue.12
, pp. 1441-1448
-
-
Sheridan, J.P.1
Zhang, Y.2
Riester, K.3
Tang, M.T.4
Efros, L.5
Shi, J.6
Harris, J.7
Vexler, V.8
Elkins, J.S.9
-
55
-
-
17644396349
-
Immunology of multiple sclerosis
-
Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
-
(2005)
Annu. Rev. Immunol.
, vol.23
, pp. 683-747
-
-
Sospedra, M.1
Martin, R.2
-
56
-
-
78650310810
-
The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling
-
Spits H., Di Santo J.P. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat. Immunol. 2011, 12(1):21-27.
-
(2011)
Nat. Immunol.
, vol.12
, Issue.1
, pp. 21-27
-
-
Spits, H.1
Di Santo, J.P.2
-
57
-
-
0029028363
-
Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta
-
Suzuki H., Kundig T.M., Furlonger C., Wakeham A., Timms E., Matsuyama T., Schmits R., Simard J.J., Ohashi P.S., Griesser H., et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 1995, 268(5216):1472-1476.
-
(1995)
Science
, vol.268
, Issue.5216
, pp. 1472-1476
-
-
Suzuki, H.1
Kundig, T.M.2
Furlonger, C.3
Wakeham, A.4
Timms, E.5
Matsuyama, T.6
Schmits, R.7
Simard, J.J.8
Ohashi, P.S.9
Griesser, H.10
-
58
-
-
0019421207
-
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells
-
Uchiyama T., Broder S., Waldmann T.A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J. Immunol. 1981, 126(4):1393-1397.
-
(1981)
J. Immunol.
, vol.126
, Issue.4
, pp. 1393-1397
-
-
Uchiyama, T.1
Broder, S.2
Waldmann, T.A.3
-
59
-
-
0019445921
-
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells
-
Uchiyama T., Nelson D.L., Fleisher T.A., Waldmann T.A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. J. Immunol. 1981, 126(4):1398-1403.
-
(1981)
J. Immunol.
, vol.126
, Issue.4
, pp. 1398-1403
-
-
Uchiyama, T.1
Nelson, D.L.2
Fleisher, T.A.3
Waldmann, T.A.4
-
60
-
-
0036200407
-
The IL-2/IL-15 receptor systems: targets for immunotherapy
-
Waldmann T.A. The IL-2/IL-15 receptor systems: targets for immunotherapy. J. Clin. Immunol. 2002, 22(2):51-56.
-
(2002)
J. Clin. Immunol.
, vol.22
, Issue.2
, pp. 51-56
-
-
Waldmann, T.A.1
-
61
-
-
33846868833
-
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey
-
Waldmann T.A. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J. Clin. Immunol. 2007, 27(1):1-18.
-
(2007)
J. Clin. Immunol.
, vol.27
, Issue.1
, pp. 1-18
-
-
Waldmann, T.A.1
-
62
-
-
77950882839
-
Interleukin 2 receptor antagonists for kidney transplant recipients
-
(CD003897)
-
Webster A.C., Ruster L.P., McGee R., Matheson S.L., Higgins G.Y., Willis N.S., Chapman J.R., Craig J.C. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst. Rev. 2010, (1). (CD003897).
-
(2010)
Cochrane Database Syst. Rev.
, Issue.1
-
-
Webster, A.C.1
Ruster, L.P.2
McGee, R.3
Matheson, S.L.4
Higgins, G.Y.5
Willis, N.S.6
Chapman, J.R.7
Craig, J.C.8
-
63
-
-
84881481249
-
Modulation of IL-2Ralpha with daclizumab for treatment of multiple sclerosis
-
Wiendl H., Gross C.C. Modulation of IL-2Ralpha with daclizumab for treatment of multiple sclerosis. Nat. Rev. Neurol. 2013, 9(7):394-404.
-
(2013)
Nat. Rev. Neurol.
, vol.9
, Issue.7
, pp. 394-404
-
-
Wiendl, H.1
Gross, C.C.2
-
64
-
-
0028784289
-
Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment
-
Willerford D.M., Chen J., Ferry J.A., Davidson L., Ma A., Alt F.W. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995, 3(4):521-530.
-
(1995)
Immunity
, vol.3
, Issue.4
, pp. 521-530
-
-
Willerford, D.M.1
Chen, J.2
Ferry, J.A.3
Davidson, L.4
Ma, A.5
Alt, F.W.6
-
65
-
-
84455208649
-
Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease
-
Wroblewski K., Sen H.N., Yeh S., Faia L., Li Z., Sran P., Gangaputra S., Vitale S., Sherry P., Nussenblatt R. Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease. Can. J. Ophthalmol. 2011, 46(4):322-328.
-
(2011)
Can. J. Ophthalmol.
, vol.46
, Issue.4
, pp. 322-328
-
-
Wroblewski, K.1
Sen, H.N.2
Yeh, S.3
Faia, L.4
Li, Z.5
Sran, P.6
Gangaputra, S.7
Vitale, S.8
Sherry, P.9
Nussenblatt, R.10
-
66
-
-
79955700857
-
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy
-
Wuest S.C., Edwan J.H., Martin J.F., Han S., Perry J.S., Cartagena C.M., Matsuura E., Maric D., Waldmann T.A., Bielekova B. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat. Med. 2011, 17(5):604-609.
-
(2011)
Nat. Med.
, vol.17
, Issue.5
, pp. 604-609
-
-
Wuest, S.C.1
Edwan, J.H.2
Martin, J.F.3
Han, S.4
Perry, J.S.5
Cartagena, C.M.6
Matsuura, E.7
Maric, D.8
Waldmann, T.A.9
Bielekova, B.10
-
67
-
-
77949301468
-
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
-
Wynn D., Kaufman M., Montalban X., Vollmer T., Simon J., Elkins J., O'Neill G., Neyer L., Sheridan J., Wang C., Fong A., Rose J.W. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010, 9(4):381-390.
-
(2010)
Lancet Neurol.
, vol.9
, Issue.4
, pp. 381-390
-
-
Wynn, D.1
Kaufman, M.2
Montalban, X.3
Vollmer, T.4
Simon, J.5
Elkins, J.6
O'Neill, G.7
Neyer, L.8
Sheridan, J.9
Wang, C.10
Fong, A.11
Rose, J.W.12
-
68
-
-
50549090768
-
High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis
-
Yeh S., Wroblewski K., Buggage R., Li Z., Kurup S.K., Sen H.N., Dahr S., Sran P., Reed G.F., Robinson R., Ragheb J.A., Waldmann T.A., Nussenblatt R.B. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J. Autoimmun. 2008, 31(2):91-97.
-
(2008)
J. Autoimmun.
, vol.31
, Issue.2
, pp. 91-97
-
-
Yeh, S.1
Wroblewski, K.2
Buggage, R.3
Li, Z.4
Kurup, S.K.5
Sen, H.N.6
Dahr, S.7
Sran, P.8
Reed, G.F.9
Robinson, R.10
Ragheb, J.A.11
Waldmann, T.A.12
Nussenblatt, R.B.13
-
69
-
-
60149085254
-
A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells
-
Yu A., Zhu L., Altman N.H., Malek T.R. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 2009, 30(2):204-217.
-
(2009)
Immunity
, vol.30
, Issue.2
, pp. 204-217
-
-
Yu, A.1
Zhu, L.2
Altman, N.H.3
Malek, T.R.4
-
70
-
-
33847054267
-
Granzyme Kcleaves the nucleosome assembly protein SET to induce single-stranded DNA nicks of targetcells
-
Zhao T., Zhang H., Guo Y., Zhang Q., Hua G., Lu H., Hou Q., Liu H., Fan Z. Granzyme Kcleaves the nucleosome assembly protein SET to induce single-stranded DNA nicks of targetcells. Cell Death Differ. 2007, 14(3):489-499.
-
(2007)
Cell Death Differ.
, vol.14
, Issue.3
, pp. 489-499
-
-
Zhao, T.1
Zhang, H.2
Guo, Y.3
Zhang, Q.4
Hua, G.5
Lu, H.6
Hou, Q.7
Liu, H.8
Fan, Z.9
|